/
DMAC
$7.22+$0.67 (+10.23%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$352.9M
54M shares
52-week range
$3.48 – $10.42
54% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Borrow rate
0.62%
Easy to borrow
Price (6 mo)
Loading chart…
Change+$2.77
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $500.0K | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Gross profit | $500.0K | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Gross margin | 100.0% | — | — | — | — | — | — | — |
| R&D | $4.5M | $7.9M | $8.2M | $8.8M | $7.8M | $13.1M | $19.1M | $24.6M |
| Operating income | −$6.8M | −$11.6M | −$12.7M | −$13.6M | −$14.0M | −$21.3M | −$26.7M | −$34.4M |
| EBITDA | −$5.6M | −$11.6M | −$12.7M | −$13.5M | −$13.6M | −$19.3M | −$24.4M | −$32.7M |
| Net income | −$5.7M | −$10.6M | −$12.3M | −$13.6M | −$13.7M | −$19.4M | −$24.4M | −$32.8M |
| Net margin | -1146.8% | — | — | — | — | — | — | — |
| EPS (diluted) | -0.74 | -0.89 | -0.78 | -0.65 | -0.52 | -0.60 | -0.60 | -0.70 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $54M | $-0.78 | $-0.82–$-0.75 | 3 |
| 2027 | $2M | $-0.84 | $-0.84–$-0.84 | 3 |
| 2028 | $7M | $-0.93 | $-1.12–$-0.57 | 3 |
| 2029 | $25M | $-0.82 | $-0.82–$-0.82 | 1 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$0.30
Price
$7.22
Implied downside
-96%
Peer comparison
DiaMedica Therapeutics Inc. Common Stock
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.
www.diamedica.com- Employees
- 35
- IPO / List date
- Nov 29, 2007
- HQ
- MINNEAPOLIS, MN
Held by traders on TradeandTell
No one on the platform currently holds DMAC.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 52,523 | $355.6K |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded DMAC yet.
